. 2015 Sep 11;9:1697–1702. doi: 10.2147/OPTH.S68595

Table 2.

Summary of anti-IL-6 or IL-6R biologics

Biologic name	Molecular target	Company	Studied dosing	Potential uses
Tocilizumab¹³,¹⁵,²⁴,²⁶,²⁷	Membrane and soluble IL-6 receptor	Genentech	4 or 8 mg/kg IV q4wk for 6 doses or 162 mg SC qwk	RA, JIA, Castleman disease, Behçet disease, systemic sclerosis, uveitis
Sarilumab³¹	Membrane and soluble IL-6 receptor	Regeneron	150–200 mg SC q2wk	RA, uveitis
Sirukumab³⁰	IL-6	Janssen	100 mg SC q2wk	RA
Olokizumab³²	IL-6	UCB	60–240 mg SC q2–4wk	RA
Clazakizumab³³	IL-6	Alder BioPharmaceuticals	80–320 mg IV on day 1, and week 8	RA
Siltuximab³⁴	IL-6	Janssen	11 mg/kg IV q3wk	Castleman disease, multiple myeloma, prostate cancer

Note: Bold denotes FDA-approved uses.

Abbreviations: IV, intravenous; RA, rheumatoid arthritis; JIA, juvenile idiopathic arthritis; SC, subcutaneous; q4wk, every 4 weeks; q2–4wk, every 2 to 4 weeks; q3wk, every 3 weeks.